Predicting productivity in early cell line development

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 10913985
APP PUB NO 20170321288A1
SERIAL NO

15525324

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates in general to the field of recombinant protein expression. In particular, the present invention relates to a method for selecting a suitable candidate cell clone for recombinant protein expression and to a host cell for recombinant protein expression, the host cell exhibiting artificially modified gene expression of at least one gene selected from the group consisting of: Fkbp10, ZdhhC6, Myrip, Actc1, AC124993.19, Runx2, AC158560.4, PlekhB1, Rps6KA2, Sept1, Sprr2k, and Flt1.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
LEK PHARMACEUTICALS D DSLOVENIA LJUBLJANA

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Blas, Marjanca Menges, SI 1 0
Gruden, Kristina Ljubljana, SI 4 2
Jamnikar, Uro{hacek over (s)} Menges, SI 2 0

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Aug 9, 2028
11.5 Year Payment $7400.00 $3700.00 $1850.00 Aug 9, 2032
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00